Skip to main content

Table 2 Univariate and Multivariate Analysis of YAP1/FAPα, and Clinical Characteristics for Recurrence-Free Survival of NPC Patients

From: Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts

YAP1

Univariate analysis

 

Multivariate analysis

 

n = 106

HR (95% CI)

p value

HR (95% CI)

p value

YAP1 Score (≥80 vs. < 80)

2.255 (0.899–5.653)

0.083

3.841 (1.356–10.883)

0.011

Treatment Daysa

1.099 (0.996–1.212)

0.06

1.203 (1.073–1.349)

0.002

BEDa

0.943 (0.805–1.103)

0.46

0.884 (0.743–1.052)

0.164

Age Group (≥48 vs. < 48)

0.641 (0.262–1.568)

0.329

0.433 (0.133–1.416)

0.166

Gender (Male vs. Female)

1.642 (0.549–4.912)

0.375

1.631 (0.409–6.501)

0.488

T-Stage (T3/4 vs. T1/2)

2.043 (0.815–5.123)

0.128

5.354 (1.416–20.249)

0.013

N-Stage (N2/3 vs. N0/1)

1.541 (0.638–3.719)

0.336

1.388 (0.484–3.979)

0.541

Chemotherapy (Yes vs. No)

0.649 (0.249–1.690)

0.376

0.620 (0.208–1.849)

0.391

Comorbidity (Yes vs. No)

0.905 (0.361–2.269)

0.832

1.825 (0.579–5.752)

0.304

Smoking (Yes vs. No)

1.384 (0.566–3.386)

0.477

1.242 (0.384–4.020)

0.717

Betel quid (Yes vs. No)

2.361 (0.941–5.925)

0.067

0.769 (0.201–2.940)

0.702

Alcohol (Yes vs. No)

3.478 (1.386–8.727)

0.008

4.211 (1.217–14.574)

0.023

FAPα

Univariate analysis

 

Multivariate analysis

 

n = 143

HR (95% CI)

p value

HR (95% CI)

p value

FAPα Score (≥80 vs. < 80)

1.259 (0.528–2.946)

0.595

1.415 (0.519–3.857)

0.497

Treatment Daysa

1.124 (1.046–1.209)

0.002

1.170 (1.063–1.288)

0.001

BEDa

1.046 (0.958–1.143)

0.313

1.060 (0.967–1.162)

0.216

Age Group (≥48 vs. < 48)

0.888 (0.385–2.049)

0.781

0.806 (0.293–2.219)

0.677

Gender (Male vs. Female)

1.311 (0.484–3.555)

0.594

0.749 (0.237–2.373)

0.624

T-Stage (T3/4 vs. T1/2)

2.209 (0.900–5.420)

0.084

2.339 (0.798–6.854)

0.121

N-Stage (N2/3 vs. N0/1)

2.428 (0.990–5.955)

0.053

2.176 (0.823–5.753)

0.117

Chemotherapy (Yes vs. No)

0.648 (0.253–1.656)

0.365

0.496 (0.164–1.500)

0.214

Comorbidity (Yes vs. No)

1.273 (0.519–3.123)

0.598

1.570 (0.569–4.332)

0.383

Smoking (Yes vs. No)

1.777 (0.725–4.359)

0.209

1.015 (0.330–3.125)

0.979

Betel quid (Yes vs. No)

2.135 (0.895–5.092)

0.087

0.947 (0.318–2.824)

0.922

Alcohol (Yes vs. No)

3.664 (1.565–8.577)

0.003

6.015 (1.839–19.669)

0.003

  1. acontinuous variable. BED Biologically effective dose, HR Hazard ratio, CI Confidence interval